Previous 10 | Next 10 |
Phio Pharmaceuticals (PHIO) announces the closing of its previously announced registered direct offering of 2.2M shares at a price of $3.42/share with gross proceeds of about $7.7M.The company intends to use the net proceeds from the offering for general working capital needs, including the d...
Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market PR Newswire MARLBOROUGH, Mass. , Feb. 17, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developin...
Phio Pharmaceuticals (PHIO) launches direct offering of ~2.2M common shares at a price of $3.42/share.Gross proceeds are ~$7.7M. Net proceeds will be used for development of immuno-oncology programs, R&D activities and for general corporate purposes.Closing date is February 17. For furt...
Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market PR Newswire MARLBOROUGH, Mass. , Feb. 12, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next ...
Are These Cheap Penny Stocks Worth The Added Risk? If you’re looking for penny stocks to buy right now , you’re among several million others with the same plan. But what are penny stocks anyway and are they worth the risk? This is a topic that continues coming up, ...
Edesa Biotech (EDSA) +97% on regulatory nod for sub set of phase2/3 EB05 COVID-19 study.Koss Corporation (KOSS) +84%.Phunware (PHUN) +65%.Vertex Energy (VTNR) +52%.Myomo (MYO) +33% on JV to manufacture and sell the company’s products in China.AIkido Pharma (AIKI) +2...
Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market PR Newswire MARLBOROUGH, Mass. , Jan. 25, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immu...
Phio Pharma ([[PHIO]] -5.5%) announces that it has entered into securities purchase agreements with certain institutional and accredited investors to raise about $14M.The company aims to raise the funds through the issuance of its common stock and warrants at a purchase price of $3.07 per sha...
Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market PR Newswire MARLBOROUGH, Mass. , Jan. 21, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-onc...
Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference PR Newswire MARLBOROUGH, Mass. , Jan. 4, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-on...
News, Short Squeeze, Breakout and More Instantly...
Phio Pharmaceuticals Corp. Company Name:
PHIO Stock Symbol:
NASDAQ Market:
Phio Pharmaceuticals Corp. Website:
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells...
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to ...
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced i...